Hypertension HT01, 2012 – 2017

Utilizing HIV/AIDS infrastructure as a gateway to chronic care of hypertension in Africa


The introduction of highly active antiretroviral therapy (HAART) has improved life expectancy but has also been found to increase the risk of hypertension, and cardiometabolic diseases in general. Limited data is available on local trends in cardiovascular risk and how non-communicable diseases (NCDs) are screened, assessed and managed in HIV positive people.

Primary research aim

The study aims to investigate the presence of cardiovascular risk factors in patients attending antiretroviral treatment facilities. Furthermore, perceptions and attitudes of HIV-clinic health care workers and attendees to co-management of HIV and non-communicable diseases will be explored. These findings are to inform intervention programs seeking to ensure optimum integrated HIV and NCD care to HIV+ individuals.

Research objectives and methodology

In phase 1, a cross-sectional survey will be conducted among people with HIV receiving care across randomly selected urban and non-urban public health facilities in Western Cape. Phase 2 uses focus groups and key-informant interviews in an exploratory design to triangulate and explore the integrated care for HIV/AIDS and NCDs simultaneously from the perspective of different role-players.

Current status

After approval of the study selected sites were invited to enroll in the study. Of the initial 30 sites put forward 5 were immediately declined by the local authorities due to other large scale on-going piloting studies in the selected areas while a further 11 sites were declined from a district level. A few of the declined sites were replaced and the present number of sites in the study are 18 (13 urban and 5 non-urban). Oversampling took place in the larger sites and a total of 640 participants have so far been screened. Although initially planned to run concurrently with phase 1 it soon became clear that it was necessary to first obtain enough knowledge about the function of the HIV treatment facilities before implementing phase 2. So far 3 focus groups and 2 key-informant interviews have been conducted.

Lessons learned so far include the challenges of conducting such a study in the protected health care facilities.



Funding organisations

  • Hypertension HT01
  • Rwanda, South Africa, Uganda
  • 2012 – 2017

Programme contact
Jamie Forrest